Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0LI2I
|
|||
Drug Name |
Imidazopyridine and triazolopyridine compound 4
|
|||
Synonyms |
PMID28067079-Compound-108
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
VANDERBILT UNIVERSITY
|
|||
Structure |
Download2D MOL |
|||
Formula |
C16H10FN7O2
|
|||
Canonical SMILES |
C1=CC(=NC=C1F)NC(=O)C2=CC(=CN3C2=NC=N3)OC4=CN=CN=C4
|
|||
InChI |
1S/C16H10FN7O2/c17-10-1-2-14(20-4-10)23-16(25)13-3-11(7-24-15(13)21-9-22-24)26-12-5-18-8-19-6-12/h1-9H,(H,20,23,25)
|
|||
InChIKey |
CBMXXEDRQZKTGZ-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Metabotropic glutamate receptor 5 (mGluR5) | Target Info | Modulator | [1] |
Target's Patent Info | Metabotropic glutamate receptor 5 (mGluR5) | Target's Patent Info | [1] | |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Gap junction | ||||
Long-term potentiation | ||||
Retrograde endocannabinoid signaling | ||||
Glutamatergic synapse | ||||
Huntington's disease | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
Metabotropic glutamate receptor group III pathway | ||||
Metabotropic glutamate receptor group I pathway | ||||
Endogenous cannabinoid signaling | ||||
Reactome | G alpha (q) signalling events | |||
Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
WikiPathways | Hypothetical Network for Drug Addiction | |||
GPCRs, Class C Metabotropic glutamate, pheromone | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.